Random start ovarian stimulation before gonadotoxic therapies in women with cancer: a systematic review and meta-analysis


SÖNMEZER M., ŞÜKÜR Y. E., Ateş C., Saçıntı K. G., Sönmezer M., ASLAN B., ...Daha Fazla

Reproductive BioMedicine Online, cilt.47, sa.6, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 47 Sayı: 6
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1016/j.rbmo.2023.103337
  • Dergi Adı: Reproductive BioMedicine Online
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, MEDLINE
  • Anahtar Kelimeler: Chemotherapy, Fertility preservation, Gonadotoxic therapies, Ovarian stimulation, Random start ovarian stimulation
  • Ankara Üniversitesi Adresli: Evet

Özet

The aim of this systematic review and meta-analysis was to quantify the effect of random start ovarian stimulation (RSOS) compared with conventional start ovarian stimulation (CSOS) in cancer patients before gonadotoxic treatment. The final analytical cohort encompassed 688 RSOS and 1076 CSOS cycles of cancer patients before gonadotoxic treatment. Eleven studies were identified by database searches of MEDLINE, Cochrane Library and cited references. The primary outcomes of interest were the number of oocytes and mature oocytes collected, the number of embryos cryopreserved and the metaphase II (MII)–antral follicle count (AFC) ratio. The studies were rated from medium to high quality (from 6 to 9) according to the Newcastle–Ottawa Quality Assessment Scale. The two protocols resulted in similar numbers of oocytes collected, MII oocytes, embryos available for cryopreservation and comparable MII–AFC and fertilization rates. The duration of ovarian stimulation was longer (standardized mean difference [SMD] 0.35, 95% CI 0.09 to 0.61; P = 0.009) and gonadotrophin consumption was higher (SMD 0.23, 95% CI 0.06 to 0.40; P = 0.009) in RSOS compared with CSOS. This systematic review and meta-analysis show that the duration of stimulation is longer, and the total gonadotrophin consumption is higher in cancer patients undergoing RSOS compared with those undergoing CSOS, with no significant effect on mature oocyte yield.